Dr. Naomi Balzer Haas Interprets the 5-Year Follow-up Updated Results of KEYNOTE-564
KEYNOTE-564 is the first global phase III clinical trial of adjuvant immunotherapy for renal cell carcinoma to achieve positive results. At the 2025 ASCO annual meeting, Dr. Naomi Balzer Haas from the Abramson Cancer Center, University of Pennsylvania presented the updated DFS (Disease-Free Survival) and OS (Overall Survival) results from the 5-year follow-up of the study. Oncology Frontier invited Dr. Naomi Balzer Haas to interpret the results at the conference site as follows.
EHA Spotlight Interview | Prof. Xiaofan Zhu: Tackling NRAS Mutation Heterogeneity—CDK6 as a Promising Therapeutic Target
The 30th Annual Congress of the European Hematology Association (EHA 2025) was held from June 12 to 15 in Milan, Italy, bringing together cutting-edge research and breakthroughs across the global hematology community. Among the highlights was an oral presentation (Abstract S170) by the team of Professor Xiaofan Zhu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study is the first to construct a single-cell atlas of pediatric NRAS-mutated myeloid malignancies, revealing mechanisms of lineage bias and identifying CDK6 as a potential therapeutic target—offering new hope for a mutation historically considered “undruggable.” Oncology Frontier – Hematology Frontier invited Prof. Zhu to discuss the key findings, translational prospects, and major developments in pediatric hematologic malignancies presented at EHA 2025.